Literature DB >> 19411905

Acute coronary syndrome.

Kristen J Overbaugh1.   

Abstract

Acute coronary syndrome (ACS) is the umbrella term for the clinical signs and symptoms of myocardial ischemia: unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. This article further defines ACS and the conditions it includes; reviews its risk factors; describes its pathophysiology and associated signs and symptoms; discusses variations in its diagnostic findings, such as cardiac biomarkers and electrocardiographic changes; and outlines treatment approaches, including drug and reperfusion therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411905     DOI: 10.1097/01.NAJ.0000351508.39509.e2

Source DB:  PubMed          Journal:  Am J Nurs        ISSN: 0002-936X            Impact factor:   2.220


  15 in total

1.  The frequency and nature of medication errors in hospitalized patients with acute coronary syndrome.

Authors:  Mostafa A Sayed Ali; Christina Milad Lobos; Mohamed Aboel-Kassem F Abdelmegid; Ahmed Moustafa El-Sayed
Journal:  Int J Clin Pharm       Date:  2017-04-03

2.  The effects of non-surgical periodontal therapy on neutrophil elastase and elastase alpha-1 proteinase inhibitor levels in GCF in periodontitis patients with or without acute coronary syndrome.

Authors:  Nezahat Arzu Kayar; Kemal Üstün; Muammer Gözlü; Seyfullah Haliloğlu; Nilgün Özlem Alptekin
Journal:  Clin Oral Investig       Date:  2021-03-09       Impact factor: 3.573

3.  Comparison of carotid arterial morphology and plaque composition between patients with acute coronary syndrome and stable coronary artery disease: a high-resolution magnetic resonance imaging study.

Authors:  Qingjun Wang; Yuan Zeng; Yong Wang; Jianming Cai; Youquan Cai; Lin Ma; Xian Xu
Journal:  Int J Cardiovasc Imaging       Date:  2011-04-06       Impact factor: 2.357

4.  Demographics and Characteristics of Patients Admitted With Acute Coronary Syndrome to the Coronary Care Unit at King Abdulaziz University.

Authors:  Siba Z Takieddin; Naif M Alghamdi; Mansour S Mahrous; Bader M Alamri; Qusai A Bafakeeh; Mohammed A Zahrani
Journal:  Cureus       Date:  2022-06-20

Review 5.  Trained Immunity as a Trigger for Atherosclerotic Cardiovascular Disease-A Literature Review.

Authors:  Natalia Anna Zieleniewska; Małgorzata Kazberuk; Małgorzata Chlabicz; Andrzej Eljaszewicz; Karol Kamiński
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

6.  Association between serum amyloid A levels and coronary heart disease: a systematic review and meta-analysis of 26 studies.

Authors:  Jielin Zhou; Yao Lu; Sufang Wang; Keyang Chen
Journal:  Inflamm Res       Date:  2020-02-22       Impact factor: 4.575

7.  Association of cardiovascular risk factors with the different presentations of acute coronary syndrome.

Authors:  Evelise Helena Fadini Reis Brunori; Camila Takáo Lopes; Agueda Maria Ruiz Zimmer Cavalcante; Vinicius Batista Santos; Juliana de Lima Lopes; Alba Lucia Bottura Leite de Barros
Journal:  Rev Lat Am Enfermagem       Date:  2014 Jul-Aug

8.  Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis.

Authors:  Raluca-Ileana Mincu; Rolf Alexander Jánosi; Dragos Vinereanu; Tienush Rassaf; Matthias Totzeck
Journal:  Sci Rep       Date:  2017-01-27       Impact factor: 4.379

9.  The association of megalin and cubilin genetic variants with serum levels of 25-hydroxvitamin D and the incidence of acute coronary syndrome in Egyptians: A case control study.

Authors:  Raghda A Elsabbagh; Mohamed F Abdel Rahman; Sally I Hassanein; Rasha S Hanafi; Reem A Assal; Gamal M Shaban; Mohamed Z Gad
Journal:  J Adv Res       Date:  2019-09-24       Impact factor: 10.479

Review 10.  The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Authors:  Marc Cohen; Deepa Iyer
Journal:  Cardiovasc Ther       Date:  2014-10       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.